Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Ralph Lauren Corp (RL) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Ralph Lauren Corp — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $303 (market cap $39.89B), while Ralph Lauren Corp trades at $393.26 (market cap $23.50B). The key difference: Alnylam Pharmaceuticals, Inc. is the larger of the two by market cap, and Ralph Lauren Corp pays a 0.95% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | RL | |
|---|---|---|
Market Cap | $39.89B | $23.50B |
Sector | Health | Consumer Cyclical |
52-Week High | $491.22 | $414.25 |
52-Week Low | $278.09 | $283.34 |
Enterprise Value | $38.15B | $24.45B |
Dividend Yield | — | 0.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Ralph Lauren (RL) trades at $394.9, up 1.89% today, with a bullish earnings trend after beating estimates for three consecutive quarters. The stock shows strong fundamentals with a 10.49% net income margin and 34.66% ROE, though technical indicators signal near-term bearish pressure. Recent news highlights brand momentum in Asia and digital expansion under its Next Great Chapter plan, supporting growth prospects.
The outlook is positive given consistent earnings beats and analyst consensus favoring a buy rating with a $446.25 price target, implying 13% upside. Key risks include premium valuation multiples and macroeconomic headwinds affecting consumer discretionary spending, but strong cash flow and margin expansion provide a solid foundation for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Ralph Lauren Corp
Founded by designer Ralph Lauren in 1967, Ralph Lauren Corp. designs, markets, and distributes lifestyle products in North America, Europe, and Asia. Its products include apparel, footwear, eyewear, jewelry, leather goods, home products, and fragrances. The company's brands include Ralph Lauren Collection, Polo Ralph Lauren, Lauren Ralph Lauren, and Double RL. Distribution channels for Ralph Lauren include wholesale (including department stores and specialty stores), retail (including company-owned retail stores and e-commerce), and licensing.
Read more on RL →
